1 Department of Surgery B, 2 Department of HPB Surgery, 3 Department of Surgery C, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Hepatobiliary Surg Nutr. 2014 Oct;3(5):317-23. doi: 10.3978/j.issn.2304-3881.2014.09.07.
Although ablation therapy has been accepted as a promising and safe technique for treatment of unrespectable hepatic tumors, investigation of its complications has been limited. A physician who performs ablation treatment of hepatic malignancies should be aware of the broad spectrum of complications. Proper management is possible only if the physician Performing ablation understands the broad spectrum of complications encountered after ablation.
TO SYSTEMATICALLY REVIEW THE COMPLICATIONS AFTER DIFFERENT ABLATION MODALITIES: Radiofrequency ablation (RFA), microwave ablation (MWA) and Nano knife for the treatment of liver tumors and analyze possible risk factors that precipitate these complications.
WE PERFORMED ELECTRONIC SEARCHES IN THE FOLLOWING DATABASES: MEDLINE, EMBASE and COCHARNE. Current trials were identified through the Internet (from January 1, 2000 to January 1, 2014). We included only studies who specific mentioned complications after liver ablation therapy (RFA/MWA/Nano knife).
A total of 2,588 publications were identified, after detailed examination only 32 publications were included in the review. The included studies involved 15,744 participants. According to the type of technique, 13,044 and 2,700 patients were included for RFA and MWA. Analysis showed a pooled mortality of 0.15% for RFA, and 0.23% for MWA.
This systematic review gathers information from controlled clinical trials and observational studies which are vulnerable to different types of bias, never the less RFA and MWA can be considered safe techniques for the treatment of liver tumors.
尽管消融治疗已被接受为治疗不可切除的肝肿瘤的一种有前途且安全的技术,但对其并发症的研究仍很有限。进行肝恶性肿瘤消融治疗的医生应了解广泛的并发症。只有在进行消融的医生了解消融后遇到的广泛并发症的情况下,才能进行适当的处理。
系统回顾不同消融方式(射频消融、微波消融和纳米刀)治疗肝肿瘤后的并发症,并分析可能导致这些并发症的危险因素。
我们在以下数据库中进行了电子检索:MEDLINE、EMBASE 和 COCHARNE。通过互联网(从 2000 年 1 月 1 日至 2014 年 1 月 1 日)确定了当前的试验。我们仅纳入了具体提到肝消融治疗(RFA/MWA/纳米刀)后并发症的研究。
共检索到 2588 篇文献,经详细检查,仅有 32 篇文献被纳入综述。纳入的研究共涉及 15744 名参与者。根据技术类型,纳入了 13044 例和 2700 例 RFA 和 MWA 的患者。分析显示,RFA 的总体死亡率为 0.15%,MWA 的死亡率为 0.23%。
本系统综述收集了来自对照临床试验和观察性研究的信息,这些研究容易受到不同类型的偏倚的影响,但 RFA 和 MWA 可以被认为是治疗肝肿瘤的安全技术。